Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AgomAb Therapeutics NVAGMB +1.96%14 Quick Ratio is 12.88 as of Jun. 2026, which is 1% above its 10-year median of 12.81. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review. Among 1,411 Biotechnology companies, AgomAb Therapeutics NV ranks better than 84.55% on this metric.
AgomAb Therapeutics NV (NAS:AGMB) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
AgomAb Therapeutics NV Quick Ratio Related Terms
AgomAb Therapeutics NV Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, AgomAb Therapeutics NV's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AgomAb Therapeutics NV Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AgomAb Therapeutics NV's Quick Ratio distribution charts can be found below:
* The bar in red indicates where AgomAb Therapeutics NV's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
AgomAb Therapeutics NV's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AgomAb Therapeutics NV (AGMB) has a Quick Ratio of 12.88 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on AgomAb Therapeutics NV and its competitors. This is near median its historical median of 12.81. Over the past decade, AgomAb Therapeutics NV's Quick Ratio has ranged from 1.61 to 19.05. According to the industry distribution chart, AgomAb Therapeutics NV ranks #218 out of 1411 companies in the Biotechnology industry, placing it in the top 15.5%.
Is AgomAb Therapeutics NV's Quick Ratio too high?
AgomAb Therapeutics NV's current Quick Ratio of 12.88 is near median its 10-year median of 12.81. Over the past 10 years, this metric has ranged from a low of 1.61 to a high of 19.05. The Biotechnology industry median Quick Ratio is 3.70. AgomAb Therapeutics NV's value of 12.88 is 248.1% above this industry median. Based on the distribution chart, AgomAb Therapeutics NV ranks #218 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's Quick Ratio compare to CRMD and RGNX?
According to the Biotechnology industry distribution chart, AgomAb Therapeutics NV ranks #218 out of 1411 companies for Quick Ratio. This places AgomAb Therapeutics NV in the top 16% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.70. AgomAb Therapeutics NV's value of 12.88 is 248.1% above this benchmark. Historically, AgomAb Therapeutics NV's own Quick Ratio has ranged from 1.61 to 19.05 over the past decade. While the company's 10-year median is 12.81 vs. the industry median of 3.70, AgomAb Therapeutics NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.70, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AgomAb Therapeutics NV's current Quick Ratio of 12.88 is 248.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on AgomAb Therapeutics NV and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AgomAb Therapeutics NV's current Quick Ratio is 12.88, which is near median its own 10-year median of 12.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current Quick Ratio of 12.88. The current Quick Ratio is 12.88, which is near median its 10-year median of 12.81 and 248.1% above the Biotechnology industry median of 3.70. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current Quick Ratio is 12.88 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score
Get the complete analysis for AGMB
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AGMB has been successfully added to your 
